Clinical evaluation of cefatrizine (CFT) on respiratory infectious disease

Antibacterial activities of cefatrizine (CFT) were examined. The growth of all 5 clinical isolates of Staphylococcus aureus was inhibited by the drug. About a half of 16 patient strains of Klebsiellapneumoniae were inhibited, but the remaining strains were not. None of 7 clinically isolated strains of Pseudomonas aeruginosa was sensitive to the drug. Clinical evaluation of cefatrizine was made on 8 patients with respiratory infectious diseases. In a patient with primary lung abscess, an excellent therapeutic effect was obtained by the oral administration of 2g daily dose of the drug. In 2 out of 4 patients with primary pneumonia, the therapeutic effect was good, but in the other two the responses were not satisfactory. Of 3 patients with secondary bacterial infections to underlying respiratory diseases, only a patient showed a good clinical and bacteriological response. The values of laboratory tests on kidney and liver functions remained in normal ranges after the administration of the drug, except for a patient in whom a moderately elevated S-GPT value was observed, probably because of co-existence of biliary tract infection.